MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

COR · NYSE

Cencora, Inc.

Health Care · Other Pharmaceuticals

Reference price$319.58As of Jul 28, 2026
Market capitalization$62.18B
52-week range$244.82–$377.54
S&P 500 portfolio weight0.09%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$300.00-6.1% vs. reference
Average$348.78+9.1% vs. reference
High$412.00+28.9% vs. reference
8 Buy2 Hold0 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportAug 5, 2026Jun 2026
Consensus EPS$4.374 estimates
Expected range$4.34–$4.43Low to high EPS
Sep 2026$17.79Street EPS consensus
Sep 2027$19.81Street EPS consensus
Sep 2028$21.70Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Sep 30, 2025.

MetricCurrentPrior
Revenue+9.3% YoY$321B$294B
Operating income$2.63B$2.18B
Net income$1.55B$1.51B
Operating cash flow$3.88B$3.48B
Capital expenditures($0.67B)($0.49B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

Zacks

Can Pharmacy Wins and Home-Based Care Boost BTSG's Q2 Results?

Zacks

Henry Schein Prepares to Report Q2 Earnings: What's in the Cards?

Zacks

HCA Q2 Earnings Beat on Strong Admissions, 2026 Outlook Revised

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.